Related Organization(s)

You just read:

Frost & Sullivan Publishes Quarterly Update on BioLineRx Ltd.: Company is on track with its execution of multiple clinical development programs for the Company's lead product - BL-8040; the company has sufficient cash until H1-2020; target price remains unchanged

News provided by

Frost & Sullivan

Jul 06, 2018, 10:38 ET